In light of the profound elevations in IL1β and IFNγ, the authors credit the use of anakinra for the positive outcomes observed, where all cases of HLH resolved (with one mortality due to bacterial sepsis) and suggest considering the use of emapalumab, a monoclonal antibody targeting IFNγ. Here, IFNG is linked to hemophagocytic syndrome.